TRAIL and RIPK3 Do Not Predict Mortality and Acute Kidney Injury in Critically Ill Patients at Admission to the Intensive Care Unit-A Single-Center Cohort Study

TRAIL 和 RIPK3 不能预测重症监护病房入院危重患者的死亡率和急性肾损伤——一项单中心队列研究

阅读:2

Abstract

TNF-related apoptosis-inducing ligand (TRAIL), a protein involved in apoptosis, and receptor-interacting serine/threonine protein kinase-3 (RIPK3), implicated in necroptosis, are known to change during organ damage and have been studied as prognostic markers in sepsis; however, cell death mechanisms also play a role in other critical illnesses. This study aimed to assess the utility of TRAIL and RIPK3 in predicting mortality and acute kidney injury (AKI) among unselected intensive care unit (ICU) patients. We performed a single-center prospective cohort study including 142 consecutive ICU admissions, collecting blood samples for TRAIL and RIPK3 measurement within 24 h of admission. The primary endpoints were in-hospital mortality and incident AKI during the ICU stay, with additional analysis of mortality over a two-year follow-up. Neither TRAIL nor RIPK3 levels at admission were significantly associated with in-hospital mortality, long-term mortality, or AKI incidence. However, higher RIPK3 levels correlated with shorter time to AKI occurrence. These results suggest that despite earlier evidence supporting their prognostic value in sepsis, TRAIL and RIPK3 did not reliably predict outcomes in a heterogeneous ICU population, underscoring the complexity of critical illness and the need for multiparametric biomarker strategies to improve risk stratification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。